Advertisement
PMN vs SYRE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PMN is a Hold and SYRE is a Hold.
Momentum Indicator for PMN turns negative, indicating new downward trend
PMN saw its Momentum Indicator move below the 0 level on September 23, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 105 similar instances where the indicator turned negative. In 99 of the 105 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PMN turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
PMN moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for PMN moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PMN entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for PMN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMN advanced for three days, in 158 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
PMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. PMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.933) is normal, around the industry mean (26.782). P/E Ratio (7.778) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for SYRE turns negative, indicating new downward trend
SYRE saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 71 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SYRE turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +7.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 255 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.924) is normal, around the industry mean (26.823). P/E Ratio (1.716) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PMN | SYRE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 52 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 68 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 96 | |
PRICE GROWTH RATING 1..100 | 87 | 37 | |
P/E GROWTH RATING 1..100 | 98 | 71 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYRE's Valuation (68) in the Pharmaceuticals Major industry is in the same range as PMN (89) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.
SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PMN (100) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.
SYRE's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as PMN (99) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.
SYRE's Price Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for PMN (87) in the null industry. This means that SYRE’s stock grew somewhat faster than PMN’s over the last 12 months.
SYRE's P/E Growth Rating (71) in the Pharmaceuticals Major industry is in the same range as PMN (98) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.
| PMN | SYRE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Advances ODDS (%) | 9 days ago 84% | 6 days ago 87% |
| Declines ODDS (%) | 4 days ago 90% | 4 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PMN’s FA Score shows that 0 FA rating(s) are green while SYRE’s FA Score has 0 green FA rating(s).
- PMN’s FA Score: 0 green, 5 red.
- SYRE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PMN’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 3 bullish TA indicator(s).
- PMN’s TA Score: 4 bullish, 6 bearish.
- SYRE’s TA Score: 3 bullish, 4 bearish.
Price Growth
PMN (@Biotechnology) experienced а -15.19% price change this week, while SYRE (@Biotechnology) price change was -6.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
Reported Earning Dates
SYRE is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-10.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GUMI | 50.24 | -0.01 | -0.01% |
| Goldman Sachs Ultra Short Municipal Income ETF (GUMI) | |||
| HYBI | 47.90 | -0.03 | -0.07% |
| NEOS Enhanced Income Credit Select ETF (HYBI) | |||
| TOPT | 34.60 | -0.46 | -1.31% |
| iShares Top 20 U.S. Stocks ETF (TOPT) | |||
| QLD | 87.72 | -4.64 | -5.02% |
| ProShares Ultra QQQ (QLD) | |||
| PILL | 13.41 | -0.91 | -6.35% |
| Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) | |||
PMN and
Correlation & Price change
A.I.dvisor indicates that over the last year, PMN has been loosely correlated with CNSP. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if PMN jumps, then CNSP could also see price increases.
| Ticker / NAME | Correlation To PMN | 1D Price Change % | ||
|---|---|---|---|---|
| PMN | 100% | -6.32% | ||
| CNSP - PMN | 51% Loosely correlated | -4.14% | ||
| SYRE - PMN | 44% Loosely correlated | -0.25% | ||
| BBIO - PMN | 42% Loosely correlated | -1.10% | ||
| ABOS - PMN | 33% Poorly correlated | +1.20% | ||
| CTNM - PMN | 33% Poorly correlated | -10.38% | ||
More | ||||
SYRE and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.
| Ticker / NAME | Correlation To SYRE | 1D Price Change % | ||
|---|---|---|---|---|
| SYRE | 100% | -0.25% | ||
| ORKA - SYRE | 51% Loosely correlated | -2.63% | ||
| BEAM - SYRE | 45% Loosely correlated | -5.10% | ||
| IMVT - SYRE | 44% Loosely correlated | -2.84% | ||
| PMN - SYRE | 44% Loosely correlated | -6.32% | ||
| PHVS - SYRE | 42% Loosely correlated | -6.41% | ||
More | ||||